Principal Financial Group Inc Kymera Therapeutics, Inc. Transaction History

Principal Financial Group Inc

  • $172 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024
SELL
$29.85 - $39.42 $116,653 - $154,053
-3,908 Reduced 32.3%
8,190 $244,000
Q1 2024

Apr 29, 2024
BUY
$22.9 - $43.57 $12,526 - $23,832
547 Added 4.74%
12,098 $486,000
Q4 2023

Feb 07, 2024
SELL
$10.97 - $26.84 $351 - $858
-32 Reduced 0.28%
11,551 $294,000
Q3 2023

Nov 02, 2023
SELL
$13.9 - $23.88 $2,015 - $3,462
-145 Reduced 1.24%
11,583 $161,000
Q2 2023

Aug 07, 2023
SELL
$22.4 - $34.92 $14,582 - $22,732
-651 Reduced 5.26%
11,728 $269,000
Q1 2023

May 09, 2023
BUY
$24.84 - $38.75 $38,079 - $59,403
1,533 Added 14.13%
12,379 $366,000
Q4 2022

Feb 09, 2023
BUY
$19.57 - $30.92 $18,924 - $29,899
967 Added 9.79%
10,846 $270,000
Q3 2022

Nov 09, 2022
BUY
$20.91 - $34.27 $206,569 - $338,553
9,879 New
9,879 $215,000
Q2 2022

Aug 10, 2022
SELL
$14.13 - $42.55 $170,238 - $512,642
-12,048 Closed
0 $0
Q1 2022

May 09, 2022
BUY
$35.3 - $64.68 $2,506 - $4,592
71 Added 0.59%
12,048 $510,000
Q4 2021

Feb 09, 2022
BUY
$49.91 - $65.56 $237,920 - $312,524
4,767 Added 66.12%
11,977 $760,000
Q3 2021

Nov 09, 2021
BUY
$47.8 - $66.66 $123,754 - $172,582
2,589 Added 56.03%
7,210 $424,000
Q2 2021

Aug 10, 2021
BUY
$31.08 - $51.95 $143,620 - $240,060
4,621 New
4,621 $224,000

Others Institutions Holding KYMR

# of Institutions
184
Shares Held
64.4M
Call Options Held
50.6K
Put Options Held
81.7K
View Full List

About Kymera Therapeutics, Inc.

KYMR Quotes by TradingView
  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.3B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Principal Financial Group Inc Portfolio

Follow Principal Financial Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Principal Financial Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email